Applied Dna Sciences Inc (NASDAQ: APDN) has experienced a decline in its stock price by -12.12 compared to its previous closing price of 0.33. However, the company has seen a fall of -15.77% in its stock price over the last five trading days. MarketBeat reported 2024-04-09 that Marketbeat’s many investor tools include analysts’ rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.
Is It Worth Investing in Applied Dna Sciences Inc (NASDAQ: APDN) Right Now?
Moreover, the 36-month beta value for APDN is 0.16. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APDN is 14.89M and currently, short sellers hold a 1.82% of that float. On April 24, 2024, APDN’s average trading volume was 122.99K shares.
APDN’s Market Performance
APDN stock saw a decrease of -15.77% in the past week, with a monthly decline of -41.88% and a quarterly a decrease of -53.89%. The volatility ratio for the week is 14.61%, and the volatility levels for the last 30 days are 10.36% for Applied Dna Sciences Inc (APDN). The simple moving average for the past 20 days is -25.89% for APDN’s stock, with a -67.75% simple moving average for the past 200 days.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -40.83% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.41% of loss for the given period.
Volatility was left at 10.36%, however, over the last 30 days, the volatility rate increased by 14.61%, as shares sank -39.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.46% lower at present.
During the last 5 trading sessions, APDN fell by -15.77%, which changed the moving average for the period of 200-days by -77.86% in comparison to the 20-day moving average, which settled at $0.3818. In addition, Applied Dna Sciences Inc saw -52.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -1.5 for the present operating margin
- 0.38 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -0.81. The total capital return value is set at -1.85. Equity return is now at value -107.64, with -47.72 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -6.8. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is 2.57.
Currently, EBITDA for the company is -10.45 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 0.3. The receivables turnover for the company is 19.96for trailing twelve months and the total asset turnover is 0.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
To wrap up, the performance of Applied Dna Sciences Inc (APDN) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
